---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-22-000054"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:23:29.045709+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Keros Q3 net loss $23.5M; cash runway extended to Q1 2025

## Summary
- Net loss of $23.5M in Q3 2022 vs $20.3M in Q3 2021, driven by higher R&D and G&A costs.
- R&D expenses $21.0M (+$6.2M YoY); G&A expenses $6.9M (+$1.6M YoY).
- Cash and cash equivalents $239.4M at Sep 30, 2022; ATM proceeds extend runway into Q1 2025.
- KER-012 Phase 1 data presented; Phase 2 PAH trial design expected early 2023.

## SEC filing metadata
- accession: 0001664710-22-000054
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/0001664710-22-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/kros-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-22-000054
- JSON: https://secwatch.observer/filing/0001664710-22-000054.json
- Plain text: https://secwatch.observer/filing/0001664710-22-000054.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $23.5 million.
  - Period: the quarter ended September 30, 2022
  - Net income: net loss of $23.5 million
  - Result: reported results
  source text: Keros reported a net loss of $23.5 million in the third quarter of 2022 as compared to a net loss of $20.3 million in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/0001664710-22-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.